HU

Hutchmed (China) Limited

HCM | HKEX

Overview

Corporate Details

ISIN(s):
KYG4672N1198 (+1 more)
LEI:
2138006X34YDQ6OBYE79
Country:
Hong Kong
Address:
LEVEL 18, THE METROPOLIS TOWER, KOWLOON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

No description available.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-03 08:30
Regulatory News Service
Updates from R&D Event
English 23.6 KB
2025-10-23 08:00
Regulatory News Service
HUTCHMED Presents Data at AACR NCI EORTC
English 20.4 KB
2025-10-21 10:30
Remuneration Information
Vesting of awards under Long Term Incentive Plan
English 41.6 KB
2025-10-14 10:30
Board/Management Information
Appointment of Independent Non-executive Director
English 20.0 KB
2025-10-13 08:05
Earnings Release
Data to be Presented at the 2025 ESMO Congress
English 23.1 KB
2025-10-02 08:00
Regulatory News Service
HUTCHMED Highlights Data to be Presented at ESMO
English 32.5 KB
2025-09-30 10:30
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 13.3 KB
2025-08-26 08:00
Board/Management Information
Directorate Change
English 17.9 KB
2025-08-20 08:00
Regulatory News Service
HUTCHMED Completes Enrollment of Phase III Trial
English 29.1 KB
2025-08-07 13:00
Earnings Release
2025 Interim Results
English 141.5 KB
2025-07-03 10:30
Report Publication Announcement
HUTCHMED to Announce 2025 Half-Year Results
English 12.1 KB
2025-06-30 10:30
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 12.4 KB
2025-06-30 10:30
Remuneration Information
Blocklisting Six Monthly Return
English 25.1 KB
2025-06-30 10:30
Regulatory News Service
China Approval based on Phase III SACHI Trial
English 29.8 KB

Automate Your Workflow. Get a real-time feed of all Hutchmed (China) Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Hutchmed (China) Limited

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Hutchmed (China) Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America ACXP
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America ADAG
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea 179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America ADCT
Addex Therapeutics Ltd. Logo
Developing novel oral allosteric modulators to treat neurological disorders.
United States of America ADXN
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America ADIL

Talk to a Data Expert

Have a question? We'll get back to you promptly.